Delcath Systems (NASDAQ:DCTH) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of Delcath Systems (NASDAQ:DCTH) in a research report sent to investors on Friday morning, Benzinga reports. They currently have a $21.00 target price on the stock.

Other equities research analysts have also issued research reports about the stock. StockNews.com lowered shares of Delcath Systems from a “hold” rating to a “sell” rating in a report on Thursday. Stephens reissued an “overweight” rating and issued a $25.00 price target on shares of Delcath Systems in a report on Tuesday, August 6th. Craig Hallum started coverage on shares of Delcath Systems in a research report on Friday, June 28th. They issued a “buy” rating and a $18.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Delcath Systems in a research report on Friday. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.50.

Delcath Systems Stock Performance

Shares of NASDAQ DCTH opened at $11.28 on Friday. The firm has a market cap of $313.43 million, a PE ratio of -4.26 and a beta of 0.78. The firm has a fifty day moving average of $9.12 and a 200 day moving average of $7.71. Delcath Systems has a one year low of $2.25 and a one year high of $11.74.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.12). The company had revenue of $7.77 million during the quarter, compared to analysts’ expectations of $5.00 million. Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. During the same period in the previous year, the firm posted ($0.58) EPS. On average, equities analysts predict that Delcath Systems will post -1.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Delcath Systems

A number of large investors have recently made changes to their positions in the stock. Rosalind Advisors Inc. grew its position in shares of Delcath Systems by 155.1% in the second quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company’s stock valued at $22,184,000 after purchasing an additional 1,611,561 shares in the last quarter. AIGH Capital Management LLC grew its position in shares of Delcath Systems by 1.7% in the second quarter. AIGH Capital Management LLC now owns 2,399,792 shares of the company’s stock valued at $20,086,000 after purchasing an additional 40,064 shares in the last quarter. BVF Inc. IL grew its position in shares of Delcath Systems by 23.1% in the first quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock valued at $5,734,000 after purchasing an additional 225,918 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Delcath Systems by 31.0% in the first quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after acquiring an additional 161,678 shares during the last quarter. Finally, Shellback Capital LP acquired a new position in Delcath Systems in the second quarter valued at approximately $1,353,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.